EGFR and neoplasm: In CTG1014, which carries EGFR L858R/T790M mutations, a single dose of 3.0 mg/ml RN765C was sufficient to induce tumor regression with similar efficacy as two doses of paclitaxel and was more efficacious than multiple doses of gemcitabine, carboplatin or cetuximab (Figure 5A).